evoke pharma inc - EVOK
EVOK
Close Chg Chg %
10.96 0.04 0.36%
Closed Market
11.00
+0.04 (0.36%)
Volume: 47.10K
Last Updated:
Dec 16, 2025, 4:00 PM EDT
Company Overview: evoke pharma inc - EVOK
EVOK Key Data
| Open $10.98 | Day Range 10.98 - 11.00 |
| 52 Week Range 1.94 - 11.00 | Market Cap N/A |
| Shares Outstanding NaN | Public Float N/A |
| Beta -0.14 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$2.38 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 31.09K |
EVOK Performance
| 1 Week | 0.00% | ||
| 1 Month | 1.10% | ||
| 3 Months | 124.49% | ||
| 1 Year | 126.34% | ||
| 5 Years | -97.28% |
EVOK Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
1
Full Ratings ➔
An error occurred while fetching the data.
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Evoke Pharma Inc - EVOK
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.62M | 2.51M | 5.18M | 10.25M | |
Sales Growth
| +6,929.00% | +55.04% | +106.51% | +97.84% | |
Cost of Goods Sold (COGS) incl D&A
| 328.12K | 370.39K | 201.88K | 356.53K | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | - | - | - | - |
Depreciation
| - | - | - | - | - |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +278.40% | +12.88% | -45.50% | +76.61% | |
Gross Income
| 1.29M | 2.14M | 4.98M | 9.89M | |
Gross Income Growth
| +2,125.31% | +65.76% | +132.84% | +98.70% | |
Gross Profit Margin
| +79.72% | +85.24% | +96.10% | +96.52% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 9.44M | 9.92M | 12.41M | 15.10M | |
Research & Development
| 590.48K | 300.79K | 181.91K | 16.32K | |
Other SG&A
| 8.85M | 9.62M | 12.23M | 15.08M | |
SGA Growth
| -27.28% | +5.11% | +25.04% | +21.66% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | (105.13K) | - |
EBIT after Unusual Expense
| (8.05M) | (7.79M) | (7.43M) | (5.20M) | |
Non Operating Income/Expense
| 8.62K | 62.01K | 138.60K | 353.31K | |
Non-Operating Interest Income
| 8.62K | 62.01K | 138.60K | 353.31K | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 500.05K | 500.00K | 500.00K | 501.37K | |
Interest Expense Growth
| - | +342.55% | -0.01% | +0.27% | |
Gross Interest Expense
| 500.05K | 500.00K | 500.00K | 501.37K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (8.54M) | (8.22M) | (7.79M) | (5.35M) | |
Pretax Income Growth
| +35.10% | +3.68% | +5.25% | +31.31% | |
Pretax Margin
| -527.66% | -327.83% | -150.41% | -52.22% | |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (8.54M) | (8.22M) | (7.79M) | (5.35M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (8.54M) | (8.22M) | (7.79M) | (5.35M) | |
Net Income Growth
| +35.10% | +3.68% | +5.25% | +31.31% | |
Net Margin Growth
| -527.66% | -327.83% | -150.41% | -52.22% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (8.54M) | (8.22M) | (7.79M) | (5.35M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (8.54M) | (8.22M) | (7.79M) | (5.35M) | |
EPS (Basic)
| -38.1989 | -31.3936 | -27.9706 | -2.8094 | |
EPS (Basic) Growth
| +48.59% | +17.82% | +10.90% | +89.96% | |
Basic Shares Outstanding
| 223.51K | 261.97K | 278.59K | 1.91M | |
EPS (Diluted)
| -38.1989 | -31.3936 | -27.9706 | -2.8094 | |
EPS (Diluted) Growth
| +48.59% | +17.82% | +10.90% | +89.96% | |
Diluted Shares Outstanding
| 223.51K | 261.97K | 278.59K | 1.91M | |
EBITDA
| (8.15M) | (7.79M) | (7.43M) | (5.20M) | |
EBITDA Growth
| +37.52% | +4.48% | +4.56% | +29.97% | |
EBITDA Margin
| -503.79% | -310.37% | -143.44% | -50.77% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 18.00 | |
| Number of Ratings | 1 | Current Quarters Estimate | N/A | |
| FY Report Date | N/A | Current Year's Estimate | N/A | |
| Last Quarter’s Earnings | -0.45 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -2.81 | Next Fiscal Year Estimate | N/A | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | N/A | N/A | N/A | N/A |
| Mean Estimate | N/A | N/A | N/A | N/A |
| High Estimates | N/A | N/A | N/A | N/A |
| Low Estimate | N/A | N/A | N/A | N/A |
| Coefficient of Variance | N/A | N/A | N/A | N/A |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 0 | 0 | 1 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Hold | Hold | Buy |
SEC Filings for Evoke Pharma Inc - EVOK
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Evoke Pharma Inc - EVOK
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Dec 18, 2025 | Todd C. Brady Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 18, 2025 | Mark A. Kowieski Chief Financial Officer | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 18, 2025 | Matthew J. D'Onofrio Chief Executive Officer; Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 18, 2025 | Matthew J. D'Onofrio Chief Executive Officer; Director | N/A | Disposition pursuant to a tender of shares in a change of control transaction | 0.00 |
| Dec 18, 2025 | Marilyn R. Carlson Chief Medical Officer | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 18, 2025 | Marilyn R. Carlson Chief Medical Officer | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 18, 2025 | Marilyn R. Carlson Chief Medical Officer | N/A | Disposition pursuant to a tender of shares in a change of control transaction | 0.00 |
| Dec 18, 2025 | Malcolm R. Hill Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 18, 2025 | Malcolm R. Hill Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 18, 2025 | Malcolm R. Hill Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 18, 2025 | Malcolm R. Hill Director | N/A | Disposition pursuant to a tender of shares in a change of control transaction | 0.00 |
| Dec 18, 2025 | Cam L. Garner Director | N/A | Disposition pursuant to a tender of shares in a change of control transaction | 0.00 |
| Dec 18, 2025 | Todd C. Brady Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 18, 2025 | Todd C. Brady Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 18, 2025 | Todd C. Brady Director | N/A | Disposition pursuant to a tender of shares in a change of control transaction | 0.00 |
| Dec 18, 2025 | Kenneth J. Widder Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 18, 2025 | Kenneth J. Widder Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 18, 2025 | Kenneth J. Widder Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 18, 2025 | Cam L. Garner Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 18, 2025 | Cam L. Garner Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |